The full mutation (FM), clinical FXS, is characterized by more than 200 CGG repeats, resulting in epigenetic silencing of the FMR1 gene via hypermethylation leading to a marked deficiency of the gene’s product: FMRP. This evidence concerns the gene FMR1 and fragile X syndrome.